scholarly journals Methanobrevibacter smithii in irritable bowel syndrome: a clinical and molecular study

2019 ◽  
Vol 91 (8) ◽  
pp. 47-51
Author(s):  
A V Vlasova ◽  
V A Isakov ◽  
V I Pilipenko ◽  
S A Sheveleva ◽  
Yu M Markova ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Breath Test ◽  
Normal Values ◽  
Molecular Study ◽  
Hydrogen Breath Test ◽  
Methanobrevibacter Smithii ◽  
Stool Samples ◽  
Small Intestinal ◽  
Irritable Bowel

Aim. To assess the role of Methanobrevibacter smithii in patients with irritable bowel syndrome associated with small intestinal bowel overgrowth. Materials and methods. Sixty - seven patients with IBS according to Rome IV were enrolled into the study in whom hydrogen breath test was performed. Thirty - two healthy subjects with negative breath test was used as a control. All IBS symptoms assessed daily with 5 grade Lykert scale for 7 days, stool was assessed by Brystol stool scale. M. smithii was confirmed in stool samples by PCR. Results and discussion. In 67 IBS patients CH4 overproduction was found in 32 (47.7%), H2 overproduction in 31 (46.2%) and normal values in 4 (5.9%) by hydrogen breath test. M. smithii was confirmed by stool PCR in all patients with CH4 overproduction. Severity and prevalence of main clinical features of IBS were similar in both SIBO groups but were significantly higher than in control (p

Probiotic Agents in the Treatment of Irritable Bowel Syndrome

2007 ◽  
Vol 35 (5) ◽  
pp. 583-589 ◽  
Author(s):  
M Guslandi
Keyword(s):  
Irritable Bowel Syndrome ◽  
Critical Evaluation ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Serotonin System ◽  
Small Intestinal ◽  
Irritable Bowel ◽  
Inflammatory Changes ◽  
Post Infectious

Irritable bowel syndrome (IBS) is characterized by abdominal pain and alterations in bowel habits. Several pathogenetic factors, such as altered intestinal motility, visceral hypersensitivity, serotonin system abnormalities and psychic disturbances have been identified. Recently, a pathogenetic role of intestinal microflora has been shown in IBS: viral or bacterial infection can trigger post-infectious IBS; some patients have small intestinal bacterial overgrowth; the composition of patients' enteric flora is altered; and minimal inflammatory changes, consistent with the pro-inflammatory role of bacteria, have been demonstrated. Probiotics may, therefore, offer a rational therapeutic approach to IBS. The data available on the use of probiotics in IBS are still limited and results of controlled clinical trials are contradictory because they have been performed using different species, dosages, treatment durations and end-points for results evaluation. A critical evaluation of the therapeutic role of the various probiotics in IBS is presented in this article.

Sign in / Sign up

Export Citation Format

Share Document